key: cord-0707425-l0kiak4b
authors: Martins, M; Carvalho, L; Carvalho, T; Gomes, I
title: Impact of the COVID-19 pandemic on in-hospital diagnosis of tuberculosis in non-HIV patients
date: 2022-05-11
journal: Pulmonology
DOI: 10.1016/j.pulmoe.2022.04.012
sha: 221f4f3b753e272c886cd4805721ad0f537ef2ca
doc_id: 707425
cord_uid: l0kiak4b

nan

pandemic has deeply affected the efforts on tuberculosis (TB) prevention, case detection and management. Reductions in TB diagnoses during the pandemic have been reported worldwide which has been attributed to a reduction in admissions due to lockdown, as well as to the abundance of public health measures directed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at the expense of other respiratory infectious diseases 2 .

In Portugal, the first COVID-19 case was recorded on the 2 nd March 2020. We We analysed a total of 100 cases (58 from pre-pandemic period and 42 from pandemic period) and the 42 cases linked with the time of pandemic reflected 72.4% of the admissions comparing to the homologous pre-pandemic one. There were fewer admissions in the first three months of the pandemic (18 in the pre-pandemic vs 7 in the pandemic, p=0.101), coinciding with a mandatory household lockdown period and in line with reports disclosing partial disruptions in TB case detection and treatment during the same three months 3 .

Patients were significantly older in the pandemic group (54.5 years vs 63.0 years, p=0.015), (Table-1 ). In both groups, most were male (75.9% in the pre-pandemic vs 78.6% in the pandemic sets, p=0.250) and had smoking history (62.1% vs 61.9%, p=0.987). Pre-existing lung disease was present in 32.8% (n=19) and 38.1% (n=16) of the patients (p=0.992), with chronic obstructive lung disease (COPD) being the most frequent among those -36.8% and 43.8%. Previous TB diagnosis was found in 6.9%, n=4 and 9.5%, n=4 of the cases in each group (p=0.805). A variety of immunosuppression status was present in 46.6% (n=27) of the patients in the pre-pandemic group vs 16.7% (n=7) in the pandemic, a difference that was statistically significant (p=0.002).

Disseminated tuberculosis was identified in 20.7% (n=12; pandemic group) and 31.0% (n=13; pre-pandemic group) of cases (p=0.324). However, a significant increase in disseminated tuberculosis in immunocompetent patients was seen in the pandemic group -n=11, 84.6% vs n=4, 33% (p=0.009) -affecting mainly bone, liver and genitourinary system. Exclusive pulmonary tuberculosis was found in 51.7% (n=30) and 47.6% (n=20) of patients (p=0.421), respectively.

Despite no difference in cavitating pulmonary disease (p=0.239), bilateral lesions were more frequent in the pandemic period -n=12, 60% vs n=9, 30% (p=0.035) -as was previously with some level of health service disruption 6 . According to our data, during the pandemic period, 95.2% (n=40) of the cases were drug-sensitive and mortality was lower (12.1%, n=7, vs. 4.8%, n=2) but no statistical difference was found (p=0.208).

In our study, less immunocompromised patients hospitalized with TB were seen in the pandemic period. Particular care with social distancing, self-quarantine and the thorough use of facial masks by these patients might have had an impact in this finding. In the pandemic setting there was: (i) a clear increase in extended pulmonary forms, (ii) a significant rise of disseminated tuberculosis cases in immunocompetent patients and (iii) a tendency to find a greater proportion of numerous bacilli on smears, indicating that people might have tolerated longer symptomatic periods before seeking medical aid, as they were reluctant to go to the hospital, leading to diagnostic delay and to an increased risk of TB transmission in households and communities.

Rodrigues et al. reached the same conclusion, finding delays in the diagnosis of tuberculosis in the outpatient tuberculosis centres (OTBC), even though they had been open during the pandemic 7 . In our population, COVID-19 did not impact in a rise of drug-resistant cases or higher mortality, but more data are needed in the following years. 

Tuberculosis and its future in the COVID-19 era: The Pulmonology series 2021

Increased detection of pulmonary tuberculosis amongst hospitalised inpatients during the COVID-19 pandemic

Impact of COVID-19 on Tuberculosis Control

Impact of the COVID-19 pandemic on tuberculosis management in Spain

Tuberculosis and COVID-19 interaction: A review of biological, clinical and public health effects